HOME
PROJECTS
MEMBERS
PUBLICATIONS
ANNOUNCEMENTS
WEBINARS
HOME
PROJECTS
MEMBERS
PUBLICATIONS
ANNOUNCEMENTS
WEBINARS
Our website uses cookies to bring you an easy and personalised browsing experience. By continuing, you consent to our cookie policy on this device. For More info, please see our Privacy Statement

ICECaP Collaboration Honored for Statistical Excellence in Accelerating Therapeutic Advances for Prostate Cancer.

The ICECaP collaboration has received the 2021 Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award, recognizing the integral role of statisticians to improve the care of men diagnosed with prostate cancer.  Full Press Release here.

Read about this Award in the American Statistical Association Membership Magazine, or Online.

New Analysis on Surrogate Endpoints Could Speed Up Prostate Cancer Trials By Two Years

New analysis presented by Dr Susan Halabi (STOPCaP Consortium) at the 2022 American Society of Clinical Oncology (ASCO) Meeting in Chicago showed that both radiographic progression free survival (defined as time from randomisation to radiographic progression as per protocol or death from any cause whichever occurred first) and clinical progression free survival (time from randomization to date of radiographic progression, symptoms, initiation of new treatments, or death, whichever occurred first) could be used as a surrogate endpoint for overall survival in metastatic hormone sensitive prostate cancer. Further validation of these surrogate endpoints in prospective trials could speed up clinical research and allow men to access new treatment almost two years earlier than the current drug development pathway. For more details on this work please click here.

New Analysis on Surrogate Endpoints Could Speed Up Prostate Cancer Trials By Two Years

Meta-analysis of individual participant data from multiple randomised trials showed that the addition of docetaxel chemotherapy to the standard hormone therapy improved the 5-year survival rate by 10% as compared to standard hormone therapy alone. The data presented by Dr Claire Vale (STOPCaP Consortium) at the 2022 American Society of Clinical Oncology (ASCO) Meeting in Chicago also showed that, whilst additional docetaxel led to a 39% overall improvement of the 5-year survival rate for men with high-volume disease, men with low-volume, metachronous disease did not benefit from the combination therapy. Results from this meta-analysis call for practice change, so that men can receive more targeted and personalised treatment of prostate cancer. For more details on this work please click here.